-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $45

Benzinga·07/10/2026 09:58:16
Listen to the news
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $42 to $45.